New Onset Generalized Myasthenia Gravis (gMG)
Immunology
Prevalence
20.0 / 100K
Incidence
1.7 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target New Onset Generalized Myasthenia Gravis (gMG)?
There are 1 clinical trial targeting New Onset Generalized Myasthenia Gravis (gMG) tracked by BioSniper.
What is the prevalence of New Onset Generalized Myasthenia Gravis (gMG)?
The estimated prevalence of New Onset Generalized Myasthenia Gravis (gMG) is approximately 20.0 per 100,000 population.
Deep-dive into New Onset Generalized Myasthenia Gravis (gMG)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis